Sign In
Buy ANTX
$5.03
-0.0800 (-1.57%)
At Close: Jun 29, 2026
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
07:00am, Thursday, 04'th Jun 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry plat
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
07:00am, Thursday, 21'st May 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today ann
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
04:01pm, Monday, 11'th May 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics der
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
04:01pm, Thursday, 07'th May 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today ann
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
04:00pm, Tuesday, 17'th Mar 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics der
AN2 Therapeutics Stock Cools Off After 90% Rally
09:52am, Wednesday, 11'th Mar 2026
AN2 Therapeutics Inc. (NASDAQ: ANTX) shares were down during Wednesday's premarket session in a volatile session. At the open, the stock recovered the losses.
AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?
02:49pm, Monday, 09'th Mar 2026
AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the clinical-stage biopharmaceutical company announced a $40 million private placement financing. Here's what investors ne
AN2 Therapeutics Announces $40 Million Private Placement Financing
07:00am, Monday, 09'th Mar 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
04:00pm, Tuesday, 03'rd Mar 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
07:00am, Tuesday, 17'th Feb 2026
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today ann
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today ann
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Friday, 09'th Jan 2026
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
04:01pm, Wednesday, 12'th Nov 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
